Merops Switch to
Inhibitors

Peptidase

Family Clan SEARCHES BLAST
MEROPS SUBMISSIONS

Other
information

Structure for peptidase S01.217: thrombin

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

 

PDB Organism Resolution Comment
1ABJ Homo sapiens 2.40 Å complex with D-Phe-Pro-Arg chloromethylketone
Catalytic residues are shown in ball-and-stick representation: His406 in purple, Asp462 in pink and Ser568 in orange. The N-terminal light chain is shown in yellow. D-Phe-Pro-Arg-chloromethane is shown in grey in ball-and-stick representation.
This browser does not have a Java Plug-in.
Get the latest Java Plug-in here.
Show surface
TERTIARY STRUCTURE DATA
Comment Resolution PDB PDBe SCOP CATH PDBSum Proteopedia Reference
Bos taurus
meizothrombin desF1 3.20 Å 1A0H 1A0H 1A0H 1A0H 1A0H 1A0H Martin et al., 1997
complex with Triatoma pallidipennis inhibitor triabin 2.60 Å 1AVG 1AVG 1AVG 1AVG 1AVG 1AVG Fuentes-Prior et al., 1997
complex with fibrinopeptide alpha 2.30 Å 1BBR 1BBR 1BBR 1BBR 1BBR 1BBR Martin et al., 1992
epsilon-thrombin; non-covalent complex with MQPA 2.20 Å 1ETR 1ETR 1ETR 1ETR 1ETR 1ETR Brandstetter et al., 1992
epsilon-thrombin; non-covalent complex with NAPAP 2.30 Å 1ETS 1ETS 1ETS 1ETS 1ETS 1ETS Brandstetter et al., 1992
epsilon-thrombin; non-covalent complex with 4-TAPAP 2.50 Å 1ETT 1ETT 1ETT 1ETT 1ETT 1ETT Brandstetter et al., 1992
alpha-thrombin; complex with hirudin variant 1 2.80 Å 1HRT 1HRT 1HRT 1HRT 1HRT 1HRT Vitali et al., 1992
complex with ecotin 2.50 Å 1ID5 1ID5 1ID5 1ID5 1ID5 1ID5 Wang et al., 2001
complex of alpha-thrombin and prethrombin-2 2.30 Å 1MKW 1MKW 1MKW 1MKW 1MKW 1MKW Malkowski et al., 1997
complex of alpha-thrombin and prethrombin-2 2.20 Å 1MKX 1MKX 1MKX 1MKX 1MKX 1MKX Malkowski et al., 1997
mature  peptidase 1.90 Å 1NL1 1NL1 1NL1 1NL1 1NL1 1NL1 Huang et al., 2003
mature  peptidase 2.30 Å 1NL2 1NL2 1NL2 1NL2 1NL2 1NL2 Huang et al., 2003
complex with rhodniin inhibitor 3.10 Å 1TBQ 1TBQ 1TBQ 1TBQ 1TBQ 1TBQ van et al., 1995
complex with rhodniin inhibitor 2.60 Å 1TBR 1TBR 1TBR 1TBR 1TBR 1TBR van et al., 1995
complex with ornithodorin 3.10 Å 1TOC 1TOC 1TOC 1TOC 1TOC 1TOC van et al., 1996
complex with fibrinopeptide A alpha (residues 7-19) 2.20 Å 1UCY 1UCY 1UCY 1UCY 1UCY 1UCY Martin et al., 1996
complex with BM14.1248 2.50 Å 1UVT 1UVT 1UVT 1UVT 1UVT 1UVT Engh et al., 1996
complex with BM12.1700 2.80 Å 1UVU 1UVU 1UVU 1UVU 1UVU 1UVU Engh et al., 1996
complex with hirudin 51-65 3.20 Å 1VIT 1VIT 1VIT 1VIT 1VIT 1VIT Vitali et al., 1996
complex with fibrinogen-AA peptide 1-23 (Phe8Tyr mutant) 2.50 Å 1YCP 1YCP 1YCP 1YCP 1YCP 1YCP Malkowski et al., 1997
mature  peptidase 3.50 Å 2A1D 2A1D 2A1D 2A1D 2A1D 2A1D Friedrich et al., 2006
mature  peptidase 3.30 Å 2HPP 2HPP 2HPP 2HPP 2HPP 2HPP Arni et al., 1993
complex with boophilin 2.35 Å 2ODY 2ODY 2ODY 2ODY 2ODY 2ODY Macedo-Ribeiro et al., 2008
prothrombin fragment 1 2.20 Å 2PF1 2PF1 2PF1 2PF1 2PF1 2PF1 Seshadri et al., 1991
prothrombin fragment 1; complex with calcium 2.20 Å 2PF2 2PF2 2PF2 2PF2 2PF2 2PF2 Soriano-Garcia et al., 1992
prothrombin fragment 1; complex with strontium 2.50 Å 2SPT 2SPT 2SPT 2SPT 2SPT 2SPT Seshadri et al., 1994
mature  peptidase 2.20 Å 3PMA 3PMA 3PMA 3PMA 3PMA 3PMA Desai et al., 2011
mature  peptidase 2.90 Å 3PMB 3PMB 3PMB 3PMB 3PMB 3PMB Desai et al., 2011
Homo sapiens
complex with aeruginosin 298A inhibitor 2.10 Å 1A2C 1A2C 1A2C 1A2C 1A2C 1A2C
complex with boronate form of hirudin II inhibitor 1.80 Å 1A3B 1A3B 1A3B 1A3B 1A3B 1A3B Skordalakes et al., 1998
complex with boronate form of hirudin II inhibitor 1.85 Å 1A3E 1A3E 1A3E 1A3E 1A3E 1A3E Skordalakes et al., 1998
complex with hirugen and (1S,7S)-7-amino-N-[(2R,3S)-7-amino-1-(cyclohexylamino)- 2-hydroxy-1-oxoheptan-3-yl]-7-benzyl-8-oxohexahydro- 1H-pyrazolo[1,2-a]pyridazine-1-carboxamide 2.12 Å 1A46 1A46 1A46 1A46 1A46 1A46 St et al., 1999
complex with hirudin I and a thiazole-containing inhibitor 1.80 Å 1A4W 1A4W 1A4W 1A4W 1A4W 1A4W Matthews et al., 1996
complex with hirugen and (1S,7S)-7-amino-7-benzyl-N-[(1S)-4-carbamimidamido- 1-(1S)-1-hydroxy-2-oxo-2-[(2-phenylethyl)amino]ethylbutyl]- 8-oxohexahydro-1H-pyrazolo[1,2-a]pyridazine- 1-carboxamide 2.06 Å 1A5G 1A5G 1A5G 1A5G 1A5G 1A5G St et al., 1999
complex with hirudin IIIB' inhibitor 2.20 Å 1A61 1A61 1A61 1A61 1A61 1A61 St et al., 1999
complex with hirulog 3 2.30 Å 1ABI 1ABI 1ABI 1ABI 1ABI 1ABI Qiu et al., 1992
complex with D-Phe-Pro-Arg chloromethylketone 2.40 Å 1ABJ 1ABJ 1ABJ 1ABJ 1ABJ 1ABJ Qiu et al., 1992
complex with hirudin variant I 2.00 Å 1AD8 1AD8 1AD8 1AD8 1AD8 1AD8 Malikayil et al., 1997
complex with hirudin I and EOC-D-Phe-Pro-azaLys-ONP inhibitor 2.00 Å 1AE8 1AE8 1AE8 1AE8 1AE8 1AE8 De et al., 1997
complex with hirudin I and CBZ-Pro-azaLys-ONP inhibitor 2.00 Å 1AFE 1AFE 1AFE 1AFE 1AFE 1AFE De et al., 1997
alpha-thrombin; complex with p-amidino-Phe-pyruvate 1.60 Å 1AHT 1AHT 1AHT 1AHT 1AHT 1AHT Chen et al., 1995
complex with hirugen and morpholino-diphenylalanine-methoxypropylboronic acid 1.85 Å 1AI8 1AI8 1AI8 1AI8 1AI8 1AI8 Bode et al., 1992
complex with hirugen and phenylmethylenecarboxy-(methyleneamino-formyl-diphenylmethyl)methy-pro-boroval 2.10 Å 1AIX 1AIX 1AIX 1AIX 1AIX 1AIX Bode et al., 1992
complex with hirugen inhibitor 2.20 Å 1AWF 1AWF 1AWF 1AWF 1AWF 1AWF Weir et al., 1998
mature  peptidase 3.00 Å 1AWH 1AWH 1AWH 1AWH 1AWH 1AWH Weir et al., 1998
complex with amino(3-[(3R,5R,14S,16S,21aR)-5,14-dihydroxy-1,4,17-trioxo-16-(2-phenylethyl)icosahydro-1H-pyrrolo[1,2-d][1,4,7,11]tetraazacyclononadecin-3-yl]propylamino)methaniminium inhibitor from sponge Theonalla 1.80 Å 1AY6 1AY6 1AY6 1AY6 1AY6 1AY6 Maryanoff et al., 1993
complex with hirugen and [[[(4S,5S)-4-[[(3S,6S,8aR)-6-azanyl-5-oxo- 6-(phenylmethyl)-1,2,3,7,8,8a-hexahydroindolizin- 3-yl]carbonylamino]-5-(1,3-benzothiazol-2- yl)-5-hydroxy-pentyl]amino]-azanyl-methylidene]azanium 2.07 Å 1B5G 1B5G 1B5G 1B5G 1B5G 1B5G St et al., 1999
Tyr225Ile mutant; complex with D-Phe-Pro-Arg-chloromethylketone 2.10 Å 1B7X 1B7X 1B7X 1B7X 1B7X 1B7X Guinto et al., 1999
complex with hirugen and benzylsulfinyl-norVal-Gly-Arg inhibitor 1.80 Å 1BA8 1BA8 1BA8 1BA8 1BA8 1BA8 Krishnan et al., 1998
complex with hirugen 2.10 Å 1BB0 1BB0 1BB0 1BB0 1BB0 1BB0 Krishnan et al., 1998
complex with inhibitor with rigid tripeptidyl aldehyde 2.10 Å 1BBO 1BBO 1BBO 1BBO 1BBO 1BBO Omichinski et al., 1992
complex with hirugen and proflavin 2.00 Å 1BCU 1BCU 1BCU 1BCU 1BCU 1BCU Conti et al., 1998
complex with SDZ 229-357 inhibitor 2.30 Å 1BHX 1BHX 1BHX 1BHX 1BHX 1BHX Wagner et al., 1998
complex with hirudin I and BMS-186282 synthetic inhibitor 2.60 Å 1BMM 1BMM 1BMM 1BMM 1BMM 1BMM Malley et al., 1996
complex with hirudin I and BMS-186282 synthetic inhibitor 2.80 Å 1BMN 1BMN 1BMN 1BMN 1BMN 1BMN Malley et al., 1996
complex with bovine pancreatic trypsin inhibitor 2.30 Å 1BTH 1BTH 1BTH 1BTH 1BTH 1BTH van et al., 1997
complex with acetyl-hirudin and (5-amidino-2-benzimidazolyl) (2-benzimidazolyl)methane 1.75 Å 1C1U 1C1U 1C1U 1C1U 1C1U 1C1U Katz et al., 1998
complex with acetyl-hirudin and bis(5-amidino-2-benzimidazolyl)methane 1.98 Å 1C1V 1C1V 1C1V 1C1V 1C1V 1C1V Katz et al., 1998
complex with acetyl-hirudin and bis(5-amidino-2-benzimidazolyl)methane ketone hydrate 1.90 Å 1C1W 1C1W 1C1W 1C1W 1C1W 1C1W Katz et al., 1998
mature  peptidase 2.10 Å 1C4U 1C4U 1C4U 1C4U 1C4U 1C4U Krishnan et al., 2000
complex with 2-(2,2-diphenyl-ethyl)-7-methyl-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo [1,2-A]pyridazine-5-carboxylic acid(4-carbamimidoyl-cyclohexylmethyl)-amide 2.10 Å 1C4V 1C4V 1C4V 1C4V 1C4V 1C4V Krishnan et al., 2000
complex with 2-(2,2-diphenyl-ethyl)-7-methyl-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1,2,4] triazolo[1,2-A]pyridazine-5-carboxylic acid [4-(2-amino-3H-imidazol-4-yl)-cyclohexyl]-amide 2.70 Å 1C4Y 1C4Y 1C4Y 1C4Y 1C4Y 1C4Y Krishnan et al., 2000
complex with hirugen and benzylsulfinyl-norVal-Gly-3-piperidyl-N-guandino-L-alaninal 2.10 Å 1CA8 1CA8 1CA8 1CA8 1CA8 1CA8 Krishnan et al., 1998
complex with 5-amidinoindole-4-benzylpiperidine inhibitor 2.07 Å 1D4P 1D4P 1D4P 1D4P 1D4P 1D4P Chirgadze et al., 1997
complex with selective non-electrophilic inhibitors having cyclohexyl moieties at p1 2.00 Å 1D6W 1D6W 1D6W 1D6W 1D6W 1D6W
complex with 2-propyl-pentanoic acid divalent inhibitor 2.30 Å 1DIT 1DIT 1DIT 1DIT 1DIT 1DIT Krishnan et al., 1996
Ser195Ala mutant; complex with fibrinopeptide a (7-16) 2.50 Å 1DM4 1DM4 1DM4 1DM4 1DM4 1DM4
complex with RWJ-51438 and hirugen 1.70 Å 1DOJ 1DOJ 1DOJ 1DOJ 1DOJ 1DOJ Recacha et al., 2000
alpha-thrombin; complex with des-Asp55 hirudin and benzamidine 3.16 Å 1DWB 1DWB 1DWB 1DWB 1DWB 1DWB Banner & Hadvary, 1991
alpha-thrombin; complex with des-Asp55 hirudin and MD-805 3.00 Å 1DWC 1DWC 1DWC 1DWC 1DWC 1DWC Banner & Hadvary, 1991
alpha-thrombin; complex with des-Asp55 hirudin and NAPAP 3.00 Å 1DWD 1DWD 1DWD 1DWD 1DWD 1DWD Banner & Hadvary, 1991
alpha-thrombin; complex with des-Asp55 hirudin and D-Phe-Pro-Arg-chloromethylketone 3.00 Å 1DWE 1DWE 1DWE 1DWE 1DWE 1DWE Banner & Hadvary, 1991
complex with thrombomodulin 2.30 Å 1DX5 1DX5 1DX5 1DX5 1DX5 1DX5
complex with haemadin 3.10 Å 1E0F 1E0F 1E0F 1E0F 1E0F 1E0F Richardson et al., 2000
complex with inhibitor P798 2.10 Å 1EOJ 1EOJ 1EOJ 1EOJ 1EOJ 1EOJ Slon-Usakiewicz et al., 2000
complex with inhibitor P628 2.10 Å 1EOL 1EOL 1EOL 1EOL 1EOL 1EOL Slon-Usakiewicz et al., 2000
alpha-thrombin; complex with hirugen and dansylArg-N-(3-ethyl-1,5-pentanediyl)amide 2.30 Å 1FPC 1FPC 1FPC 1FPC 1FPC 1FPC Mathews & Tulinsky, 1995
alpha-thrombin; complex with hirudin and fibrinopeptide A 2.50 Å 1FPH 1FPH 1FPH 1FPH 1FPH 1FPH Stubbs et al., 1992
complex with bch-10556 andexosite-directed peptide 2.00 Å 1G37 1G37 1G37 1G37 1G37 1G37
complex with hirudin I and N-[(benzyloxy)carbonyl]-beta-phenyl-D-phenylalanyl- N-(1S,3E)-1-[dihydroxy(diphenoxy)-lambda~5~- phosphanyl]-4-methoxybut-3-en-1-yl-L-prolinamide 1.40 Å 1H8D 1H8D 1H8D 1H8D 1H8D 1H8D Skordalakes et al., 2001
complex with hirudin I and N-[(benzyloxy)carbonyl]-beta-phenyl-D-phenylalanyl- N-[(1S)-4-methoxy-1-phosphonobutyl]-L-prolinamide 1.75 Å 1H8I 1H8I 1H8I 1H8I 1H8I 1H8I Skordalakes et al., 2001
prethrombin; complex with hirugen 2.30 Å 1HAG 1HAG 1HAG 1HAG 1HAG 1HAG Vijayalakshmi et al., 1994
alpha-thrombin; complex with hirugen 2.30 Å 1HAH 1HAH 1HAH 1HAH 1HAH 1HAH Vijayalakshmi et al., 1994
alpha-thrombin; complex with D-Phe-Pro-Arg-chloromethylketone 2.40 Å 1HAI 1HAI 1HAI 1HAI 1HAI 1HAI Vijayalakshmi et al., 1994
alpha-thrombin; complex with 15-mer oligonucleotide 2.80 Å 1HAO 1HAO 1HAO 1HAO 1HAO 1HAO Padmanabhan & Tulinsky, 1996
alpha-thrombin; complex with 15-mer oligonucleotide 2.80 Å 1HAP 1HAP 1HAP 1HAP 1HAP 1HAP Padmanabhan & Tulinsky, 1996
alpha-thrombin; complex with a peptidyl pyridinium methyl ketone 2.00 Å 1HBT 1HBT 1HBT 1HBT 1HBT 1HBT Rehse et al., 1995
alpha-thrombin; complex with hirugen 2.60 Å 1HDT 1HDT 1HDT 1HDT 1HDT 1HDT Tabernero et al., 1995
alpha-thrombin; complex with hirugen 2.20 Å 1HGT 1HGT 1HGT 1HGT 1HGT 1HGT Skrzypczak-Jankun et al., 1991
alpha-thrombin; complex with thrombomodulin and D-Phe-Pro-Arg-chloromethylketone 3.00 Å 1HLT 1HLT 1HLT 1HLT 1HLT 1HLT Mathews et al., 1994
alpha-thrombin; complex with DNA and D-Phe-Pro-Arg-chloromethylketone 2.90 Å 1HUT 1HUT 1HUT 1HUT 1HUT 1HUT Padmanabhan et al., 1993
complex with hirudin variant 1 2.10 Å 1HXE 1HXE 1HXE 1HXE 1HXE 1HXE Zhang & Tulinsky, 1997
complex with hiruden variant 2.10 Å 1HXF 1HXF 1HXF 1HXF 1HXF 1HXF Zhang & Tulinsky, 1997
alpha-thrombin; complex with hirutonin-2 2.00 Å 1IHS 1IHS 1IHS 1IHS 1IHS 1IHS Zdanov et al., 1993
alpha-thrombin; complex with hirutonin-6 2.10 Å 1IHT 1IHT 1IHT 1IHT 1IHT 1IHT Zdanov et al., 1993
Ser195Ala; complex with heparin cofactor II 2.20 Å 1JMO 1JMO 1JMO 1JMO 1JMO 1JMO Baglin et al., 2002
complex with a novel bicyclic lactam inhibitor 2.50 Å 1JWT 1JWT 1JWT 1JWT 1JWT 1JWT
complex with acetyl-D-Phe-Pro-boroArg-OH inhibitor 1.95 Å 1LHC 1LHC 1LHC 1LHC 1LHC 1LHC Weber et al., 1995
complex with acetyl-D-Phe-Pro-boroLys-OH inhibitor 2.35 Å 1LHD 1LHD 1LHD 1LHD 1LHD 1LHD Weber et al., 1995
complex with AC-D-Phe-Pro-boro-N-butyl-amidino-Gly-OH 2.25 Å 1LHE 1LHE 1LHE 1LHE 1LHE 1LHE Weber et al., 1995
complex with AC-D-Phe-Pro-boro-homoLys-OH 2.40 Å 1LHF 1LHF 1LHF 1LHF 1LHF 1LHF Weber et al., 1995
complex with AC-D-Phe-Pro-boroornithine-OH 2.25 Å 1LHG 1LHG 1LHG 1LHG 1LHG 1LHG Weber et al., 1995
anticoagulant slow form 2.80 Å 1MH0 1MH0 1MH0 1MH0 1MH0 1MH0 Pineda et al., 2002
alpha-thrombin; non-covalent complex with receptor based peptide NRS 3.10 Å 1NRN 1NRN 1NRN 1NRN 1NRN 1NRN Mathews et al., 1994
alpha-thrombin; non-covalent complex with receptor based peptide NRP 3.10 Å 1NRO 1NRO 1NRO 1NRO 1NRO 1NRO Mathews et al., 1994
alpha-thrombin; non-covalent complex with receptor based peptide NR'S 3.00 Å 1NRP 1NRP 1NRP 1NRP 1NRP 1NRP Mathews et al., 1994
alpha-thrombin; non-covalent complex with receptor based peptide D-FPR'S 3.50 Å 1NRQ 1NRQ 1NRQ 1NRQ 1NRQ 1NRQ Mathews et al., 1994
alpha-thrombin; non-covalent complex with receptor based peptide XA and D-Phe-Pro-Arg-chloromethylketone 2.40 Å 1NRR 1NRR 1NRR 1NRR 1NRR 1NRR Mathews et al., 1994
alpha-thrombin; non-covalent complex with receptor based peptide NRP and hirugen 2.40 Å 1NRS 1NRS 1NRS 1NRS 1NRS 1NRS Mathews et al., 1994
complex with staphylocoagulase 2.20 Å 1NU7 1NU7 1NU7 1NU7 1NU7 1NU7 Friedrich et al., 2003
staphylocoagulase-prethrombin-2 complex 2.20 Å 1NU9 1NU9 1NU9 1NU9 1NU9 1NU9
d-phe-pro-arg-type thrombin inhibitor 2.18 Å 1NZQ 1NZQ 1NZQ 1NZQ 1NZQ 1NZQ
complex with a D-Phe-Pro-Arg-type inhibitor and a C-terminal hirudin derived exo-site inhibitor 2.44 Å 1O0D 1O0D 1O0D 1O0D 1O0D 1O0D
dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial Ala190 protease (ala190 upa) 1.75 Å 1O5G 1O5G 1O5G 1O5G 1O5G 1O5G
complex with platelet receptor gpib-alpha 2.30 Å 1OOK 1OOK 1OOK 1OOK 1OOK 1OOK
complex with a designed fluorinated inhibitor 1.67 Å 1OYT 1OYT 1OYT 1OYT 1OYT 1OYT
complex with platelet receptor gpib-alpha 2.60 Å 1P8V 1P8V 1P8V 1P8V 1P8V 1P8V
alpha-thrombin; complex with D-Phe-Pro-Arg chloromethylketone 1.92 Å 1PPB 1PPB 1PPB 1PPB 1PPB 1PPB Bode et al., 1989
complex with [phenylalaninyl-prolinyl]-[2-(pyridin-4-ylamino)-ethyl]-amine 1.80 Å 1QBV 1QBV 1QBV 1QBV 1QBV 1QBV Bone et al., 1998
complex with hirugen and Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-sulfonated Tyr-Leu 2.20 Å 1QHR 1QHR 1QHR 1QHR 1QHR 1QHR Jhoti et al., 1999
complex with hirugen and Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-sulfonated Tyr-Leu 2.20 Å 1QJ6 1QJ6 1QJ6 1QJ6 1QJ6 1QJ6 Jhoti et al., 1999
complex with hirugen and Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-sulfonated Tyr-Leu 2.20 Å 1QJ7 1QJ7 1QJ7 1QJ7 1QJ7 1QJ7 Jhoti et al., 1999
complex with hirugen and Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-sulfonated Tyr-Leu 2.00 Å 1QJI 1QJI 1QJI 1QJI 1QJI 1QJI Grams et al., 1996
complex with bivalent, benzamidine-based synthetic inhibitor BZA-2 hirulog 2.00 Å 1QUR 1QUR 1QUR 1QUR 1QUR 1QUR Steinmetzer et al., 1999
variant Glu217Lys 2.50 Å 1RD3 1RD3 1RD3 1RD3 1RD3 1RD3
complex with natural product inhibitor oscillarin 2.04 Å 1RIW 1RIW 1RIW 1RIW 1RIW 1RIW Hanessian et al., 2004
fast form mutant Arg77Ala; complex with PPACK 1.91 Å 1SFQ 1SFQ 1SFQ 1SFQ 1SFQ 1SFQ
procoagulant fast form 2.30 Å 1SG8 1SG8 1SG8 1SG8 1SG8 1SG8
anticoagulant slow form 2.30 Å 1SGI 1SGI 1SGI 1SGI 1SGI 1SGI
slow form; complex with PPACK 1.55 Å 1SHH 1SHH 1SHH 1SHH 1SHH 1SHH
antithrombin-anhydrothrombin-heparin ternary complex structure 3.10 Å 1SR5 1SR5 1SR5 1SR5 1SR5 1SR5 Dementiev et al., 2004
complex with a novel oxyguanidine 2.00 Å 1T4U 1T4U 1T4U 1T4U 1T4U 1T4U
complex with a novel oxyguanidine 2.00 Å 1T4V 1T4V 1T4V 1T4V 1T4V 1T4V
complex with antithrombin and thrombin 2.50 Å 1TB6 1TB6 1TB6 1TB6 1TB6 1TB6 Li et al., 2004
complex with exosite-hirugen and trifluoroacetate inhibitor 2.30 Å 1TBZ 1TBZ 1TBZ 1TBZ 1TBZ 1TBZ Matthews et al., 1996
Tyr225Pro mutant; complex with D-Phe-Pro-Arg-chloromethylketone 2.10 Å 1THP 1THP 1THP 1THP 1THP 1THP Guinto et al., 1999
alpha-thrombin; complex with hirullin 2.30 Å 1THR 1THR 1THR 1THR 1THR 1THR Qiu et al., 1993
alpha-thrombin; complex with MDL-28050 2.20 Å 1THS 1THS 1THS 1THS 1THS 1THS Qiu et al., 1993
alpha-thrombin; complex with hirugen and cyclotheonamide A 2.30 Å 1TMB 1TMB 1TMB 1TMB 1TMB 1TMB Maryanoff et al., 1993
alpha-thrombin; complex with CGP 50,856 2.20 Å 1TMT 1TMT 1TMT 1TMT 1TMT 1TMT Priestle et al., 1993
alpha-thrombin; complex with hirudin fragment and D-Phe-Pro-Arg chloromethylketone 2.50 Å 1TMU 1TMU 1TMU 1TMU 1TMU 1TMU Priestle et al., 1993
complex with hirugen 1.80 Å 1TOM 1TOM 1TOM 1TOM 1TOM 1TOM
anticoagulant mutant Trp215Ala/Glu217Ala in free form 2.80 Å 1TQ0 1TQ0 1TQ0 1TQ0 1TQ0 1TQ0
anticoagulant mutant Trp215Ala/Glu217Ala; complex with PPACK 2.40 Å 1TQ7 1TQ7 1TQ7 1TQ7 1TQ7 1TQ7
complex with hirugen and NA-(N,N-dimethylcarbamoyl)-alpha-azalysine 2.00 Å 1UMA 1UMA 1UMA 1UMA 1UMA 1UMA Nardini et al., 1996
complex with BM51.1011 2.80 Å 1UVS 1UVS 1UVS 1UVS 1UVS 1UVS Engh et al., 1996
complex with Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu (t-plasminogen activator loop) 1.90 Å 1VR1 1VR1 1VR1 1VR1 1VR1 1VR1 Dekker et al., 1999
complex with heparin 1.85 Å 1XMN 1XMN 1XMN 1XMN 1XMN 1XMN
complex with a p2 pyridine n-oxide inhibitor 1.80 Å 1Z71 1Z71 1Z71 1Z71 1Z71 1Z71
Gly193Ala mutant; complex with PPACK 2.00 Å 1Z8I 1Z8I 1Z8I 1Z8I 1Z8I 1Z8I
complex with an oxazolopyridine inhibitor 21 2.20 Å 1ZGI 1ZGI 1ZGI 1ZGI 1ZGI 1ZGI
complex with an oxazolopyridine inhibitor 2 2.20 Å 1ZGV 1ZGV 1ZGV 1ZGV 1ZGV 1ZGV
in 400 mm potassium chloride 1.90 Å 2A0Q 2A0Q 2A0Q 2A0Q 2A0Q 2A0Q
orally active thrombin inhibitors in complex with thrombin inh12 2.44 Å 2A2X 2A2X 2A2X 2A2X 2A2X 2A2X
complex with the central "E" region of fibrin 3.65 Å 2A45 2A45 2A45 2A45 2A45 2A45
sodium free state 1.93 Å 2AFQ 2AFQ 2AFQ 2AFQ 2AFQ 2AFQ
orally active thrombin inhibitors in complex with thrombin and an exosite decapeptide 2.46 Å 2ANK 2ANK 2ANK 2ANK 2ANK 2ANK
ternary complex with an orally active thrombin inhibitor and a c-terminal hirudin derived exo-sit inhibitor 2.40 Å 2ANM 2ANM 2ANM 2ANM 2ANM 2ANM
two Ser195Ala mutant molecules; nonproductive complex with antithrombin and synthetic heparin mimetic sr123781 2.10 Å 2B5T 2B5T 2B5T 2B5T 2B5T 2B5T Johnson et al., 2006
complex with inhibitor 1.61 Å 2BDY 2BDY 2BDY 2BDY 2BDY 2BDY
complex with fragment-based small molecules occupying the s1 pocket 1.25 Å 2BVR 2BVR 2BVR 2BVR 2BVR 2BVR
complex with fragment-based small molecules occupying the s1 pocket 1.40 Å 2BVS 2BVS 2BVS 2BVS 2BVS 2BVS
design and discovery of novel, potent thrombin inhibitors with a solubilizing cationic p1-p2-linker 3.20 Å 2BVX 2BVX 2BVX 2BVX 2BVX 2BVX
design and discovery of novel, potent thrombin inhibitors with a solubilizing cationic p1-p2-linker 1.83 Å 2BXT 2BXT 2BXT 2BXT 2BXT 2BXT
design and discovery of novel, potent thrombin inhibitors with a solubilizing cationic p1-p2-linker 2.80 Å 2BXU 2BXU 2BXU 2BXU 2BXU 2BXU
complex with a designed inhibitor 1.30 Å 2CN0 2CN0 2CN0 2CN0 2CN0 2CN0
orally active thrombin inhibitors 2.44 Å 2FEQ 2FEQ 2FEQ 2FEQ 2FEQ 2FEQ
orally active thrombin inhibitors 2.42 Å 2FES 2FES 2FES 2FES 2FES 2FES
slow form in a self- inhibited conformation 1.87 Å 2GP9 2GP9 2GP9 2GP9 2GP9 2GP9
complex with suramin 2.40 Å 2H9T 2H9T 2H9T 2H9T 2H9T 2H9T
alpha-thrombin; complex with hirugen and fibrinopeptide A mimic 2.50 Å 2HAT 2HAT 2HAT 2HAT 2HAT 2HAT Mathews & Tulinsky, 1995
alpha-thrombin; complex with hirulog 1 2.20 Å 2HGT 2HGT 2HGT 2HGT 2HGT 2HGT Skrzypczak-Jankun et al., 1991
gamma-thrombin 2.50 Å 2HNT 2HNT 2HNT 2HNT 2HNT 2HNT Rydel et al., 1994
alpha-thrombin; complex with D-Phe-Pro-Arg chloromethylketone and bovine prothrombin fragment 2 3.30 Å 2HPP 2HPP 2HPP 2HPP 2HPP 2HPP Arni et al., 1993
alpha-thrombin; complex with D-Phe-Pro-Arg chloromethylketone and bovine prothrombin fragment 2 3.30 Å 2HPQ 2HPQ 2HPQ 2HPQ 2HPQ 2HPQ
complex with hirugen 1.70 Å 2JH0 2JH0 2JH0 2JH0 2JH0 2JH0
complex with hirugen 2.50 Å 2JH5 2JH5 2JH5 2JH5 2JH5 2JH5
complex with hirugen 2.21 Å 2JH6 2JH6 2JH6 2JH6 2JH6 2JH6
human thrombin chimera with human residues 184a, 186, 186a, 186b, 186cand 222 replaced by murine thrombin equivalents. 1.75 Å 2OD3 2OD3 2OD3 2OD3 2OD3 2OD3
inhibitor-free human thrombin mutant c191a-c220a 1.54 Å 2PGB 2PGB 2PGB 2PGB 2PGB 2PGB
Cys191Ala-Cys220Ala mutant; complex with the inhibitor PPACK 1.80 Å 2PGQ 2PGQ 2PGQ 2PGQ 2PGQ 2PGQ
complex with 4-([4-(3-methylbenzoyl)pyridin-2-yl]aminomethyl)benzenecarboximidamide 2.50 Å 2PKS 2PKS 2PKS 2PKS 2PKS 2PKS Blomberg et al., 2007
complex with sulfo-hirudin 1.84 Å 2PW8 2PW8 2PW8 2PW8 2PW8 2PW8 Liu et al., 2007
Tyr225Phe mutant; complex with D-Phe-Pro-Arg-chloromethylketone 2.10 Å 2THF 2THF 2THF 2THF 2THF 2THF Guinto et al., 1999
thrombin with 3-cycle no f 1.79 Å 2V3H 2V3H 2V3H 2V3H 2V3H 2V3H
complex with heparin and PCI 1.60 Å 3B9F 3B9F 3B9F 3B9F 3B9F 3B9F
crystal structure of thrombin bound to the extracellular fragment of par1 2.20 Å 3BEF 3BEF 3BEF 3BEF 3BEF 3BEF
slow form in a self_inhibited conformation 1.55 Å 3BEI 3BEI 3BEI 3BEI 3BEI 3BEI
thrombin:suramin complex 2.50 Å 3BF6 3BF6 3BF6 3BF6 3BF6 3BF6
complex with inhibitor fm19 1.80 Å 3BV9 3BV9 3BV9 3BV9 3BV9 3BV9
complex with inhibitor 15 1.84 Å 3C1K 3C1K 3C1K 3C1K 3C1K 3C1K
cyanofluorophenylacetamides as orally efficacious thrombin inhibitors 2.18 Å 3C27 3C27 3C27 3C27 3C27 3C27
complex with inhibitor 1.80 Å 3DA9 3DA9 3DA9 3DA9 3DA9 3DA9
complex with an RNA aptamer bound 1.90 Å 3DD2 3DD2 3DD2 3DD2 3DD2 3DD2
meizothrombin desf1 2.10 Å 3E6P 3E6P 3E6P 3E6P 3E6P 3E6P
Trp215Ala/Glu217Ala mutant 2.75 Å 3EE0 3EE0 3EE0 3EE0 3EE0 3EE0
mutant delta(146-149e) in the free form 1.55 Å 3GIC 3GIC 3GIC 3GIC 3GIC 3GIC
Na-free form; complex with thrombomodulin 2.40 Å 3GIS 3GIS 3GIS 3GIS 3GIS 3GIS
alpha-thrombin; complex with hirugen and fibrinopeptide A mimic 2.50 Å 3HAT 3HAT 3HAT 3HAT 3HAT 3HAT Mathews & Tulinsky, 1995
Trp215Ala/Glu217Ala mutant; complex withthe extracellular fragment of human par1 2.60 Å 3HKJ 3HKJ 3HKJ 3HKJ 3HKJ 3HKJ
alpha-thrombin; complex with recombinant hirudin variant 2 2.30 Å 3HTC 3HTC 3HTC 3HTC 3HTC 3HTC Rydel et al., 1990
Asn143Pro mutant in e:na+ form 1.60 Å 3JZ1 3JZ1 3JZ1 3JZ1 3JZ1 3JZ1
Asn143Pro mutant in e* form 2.40 Å 3JZ2 3JZ2 3JZ2 3JZ2 3JZ2 3JZ2
precursor; complex with fragment-2 1.85 Å 3K65 3K65 3K65 3K65 3K65 3K65
Ser195Ala mutant; complex with the extracellular fragment of human par1 1.80 Å 3LU9 3LU9 3LU9 3LU9 3LU9 3LU9
precursor 2.20 Å 3NXP 3NXP 3NXP 3NXP 3NXP 3NXP
structural basis of thrombin mediated factor v activation: essential role of the hirudin-like sequence glu666-glu672 for processing at theheavy chain-b domain junction 1.70 Å 3P6Z 3P6Z 3P6Z 3P6Z 3P6Z 3P6Z
structural basis of thrombin-mediated factor v activation: essential role of the hirudin-like sequence glu666-glu672 for processing at theheavy chain-b domain junction 2.55 Å 3P70 3P70 3P70 3P70 3P70 3P70
mechanism of sulfotyrosine-mediated glycoprotein ib interaction with two distinct alpha-thrombin sites 3.20 Å 3PMH 3PMH 3PMH 3PMH 3PMH 3PMH
complex with benzothiazole guanidine 1.65 Å 3PO1 3PO1 3PO1 3PO1 3PO1 3PO1
Asp102Asn mutant; complex with the extracellular fragment of human par4. 2.80 Å 3QDZ 3QDZ 3QDZ 3QDZ 3QDZ 3QDZ
the allosteric e*-e equilibrium is a key property of the trypsin fold 2.10 Å 3QGN 3QGN 3QGN 3QGN 3QGN 3QGN
complex with a modified thrombin binding aptamer (mtba) 2.14 Å 3QLP 3QLP 3QLP 3QLP 3QLP 3QLP
human thrombin with residues 145-150 of murine thrombin. 1.75 Å 3R3G 3R3G 3R3G 3R3G 3R3G 3R3G
Tyr225Pro mutant in the e* form 1.90 Å 3S7H 3S7H 3S7H 3S7H 3S7H 3S7H
Tyr225Pro mutant in the e form 1.90 Å 3S7K 3S7K 3S7K 3S7K 3S7K 3S7K
prethrombin-2 mutant Ser195Ala in the alternative form 1.90 Å 3SQE 3SQE 3SQE 3SQE 3SQE 3SQE
prethrombin-2 mutant Ser195Ala in the the open form 2.20 Å 3SQH 3SQH 3SQH 3SQH 3SQH 3SQH
unliganded wild-type 1.55 Å 3U69 3U69 3U69 3U69 3U69 3U69
complex with D-Phe-Pro-D-Arg-D-Thr 1.28 Å 3U8O 3U8O 3U8O 3U8O 3U8O 3U8O
complex with D-Phe-Pro-D-Arg-Ile 1.47 Å 3U8R 3U8R 3U8R 3U8R 3U8R 3U8R
complex with D-Phe-Pro-D-Arg-Cys 1.86 Å 3U8T 3U8T 3U8T 3U8T 3U8T 3U8T
complex with thrombin 2.60 Å 4BOH 4BOH 4BOH 4BOH 4BOH 4BOH
low-salt crystal structure; complex with GPIBalpha peptide 1.60 Å 4CH2 4CH2 4CH2 4CH2 4CH2 4CH2
high-salt crystal structure; complex with GPIBalpha peptide 1.75 Å 4CH8 4CH8 4CH8 4CH8 4CH8 4CH8
complex with thrombin binding aptamer in the presence of sodium ions 1.80 Å 4DIH 4DIH 4DIH 4DIH 4DIH 4DIH
complex with thrombin binding aptamer in the presence of potassium ions 2.05 Å 4DII 4DII 4DII 4DII 4DII 4DII
complex with anophelin 2.30 Å 4E05 4E05 4E05 4E05 4E05 4E05 Figueiredo et al., 2012
complex with anophelin 3.20 Å 4E06 4E06 4E06 4E06 4E06 4E06 Figueiredo et al., 2012
crystal structure of thrombin mutant Glu14ea/Asp14la/Glu18Ala/Ser195Ala 2.19 Å 4H6S 4H6S 4H6S 4H6S 4H6S 4H6S
crystal structure of prethrombin-2 mutant e14ea/d14la/e18a/s195a 2.40 Å 4H6T 4H6T 4H6T 4H6T 4H6T 4H6T
Ser195Ala mutant; complex with argatroban 2.40 Å 4HFP 4HFP 4HFP 4HFP 4HFP 4HFP
alpha-thrombin; complex with recombinant hirudin variant 2 2.30 Å 4HTC 4HTC 4HTC 4HTC 4HTC 4HTC Rydel et al., 1991
recombinant Gla-domainless prothrombin mutant Ser525Ala 3.30 Å 4HZH 4HZH 4HZH 4HZH 4HZH 4HZH
complex with a 27-mer aptamer bound to exosite ii 2.40 Å 4I7Y 4I7Y 4I7Y 4I7Y 4I7Y 4I7Y
complex with the tba deletion mutant lacking thymine 12 nucleobase 1.65 Å 4LZ1 4LZ1 4LZ1 4LZ1 4LZ1 4LZ1
complex with the tba deletion mutant lacking thymine 3 nucleobase 2.56 Å 4LZ4 4LZ4 4LZ4 4LZ4 4LZ4 4LZ4
crystal structure of ca2+-free prothrombin deletion mutant residues 146-167 2.81 Å 4NZQ 4NZQ 4NZQ 4NZQ 4NZQ 4NZQ
crystal structure of ca2+ bound prothrombin deletion mutant residues 146-167 3.38 Å 4O03 4O03 4O03 4O03 4O03 4O03
Ser195Thr mutant (free form) 1.70 Å 4RKJ 4RKJ 4RKJ 4RKJ 4RKJ 4RKJ
Ser195Thr mutant; complex with PPACK 1.84 Å 4RKO 4RKO 4RKO 4RKO 4RKO 4RKO
Ser195Ala mutant; complex with the active site inhibitor argatroban 3.00 Å 4RN6 4RN6 4RN6 4RN6 4RN6 4RN6
complex with hirunorm IV inhibitor 2.50 Å 4THN 4THN 4THN 4THN 4THN 4THN Lombardi et al., 1999
complex with 4-(((1-((2s)-1-((2r)-2-( benzylsulfonylamino)-3-phenyl-propanoyl)pyrrolidin-2-yl)-1- oxo-ethyl)amino)methyl)benzamidine 1.43 Å 4UFD 4UFD 4UFD 4UFD 4UFD 4UFD
complex with (2r)-2-(benzylsulfonylamino)-n-(2-( (4-carbamimidoylphenyl)methylamino)-2-oxo-butyl)-3-phenyl- propanamide 1.59 Å 4UFE 4UFE 4UFE 4UFE 4UFE 4UFE
complex with (2r)-2-(benzylsulfonylamino)-n-(2-( (4-carbamimidoylphenyl)methylamino)-2-oxo-ethyl)-n-methyl- 3-phenyl-propanamide 1.55 Å 4UFF 4UFF 4UFF 4UFF 4UFF 4UFF
complex with (2r)-2-(benzylsulfonylamino)-n-(( 1s)-2-((4-carbamimidoylphenyl)methylamino)-1-methyl-2-oxo- ethyl)-n-methyl-3-phenyl-propanamide ethane 1.65 Å 4UFG 4UFG 4UFG 4UFG 4UFG 4UFG
thrombin inhibitor 1.40 Å 5A2M 5A2M 5A2M 5A2M 5A2M 5A2M
complex with 3-chloro-benzamide 1.12 Å 5AFY 5AFY 5AFY 5AFY 5AFY 5AFY
complex with (2r)-2-(benzylsulfonylamino)-n-(2-( (4-carbamimidoylphenyl)methylamino)-2-oxo-propyl)-3-phenyl- propanamide 1.53 Å 5AFZ 5AFZ 5AFZ 5AFZ 5AFZ 5AFZ
complex with ((4-chlorophenyl)sulfamoyl))diemethylamine 1.24 Å 5AHG 5AHG 5AHG 5AHG 5AHG 5AHG
complex with a duplex/quadruplex 31-mer DNA aptamer 2.98 Å 5CMX 5CMX 5CMX 5CMX 5CMX 5CMX
complex with RNA aptamer 1.86 Å 5DO4 5DO4 5DO4 5DO4 5DO4 5DO4
complex with an exosite 1-specific IgA Fab 1.90 Å 5E8E 5E8E 5E8E 5E8E 5E8E 5E8E
prothrombin deletion mutant residues 146-167 ( form ii ). 3.21 Å 5EDK 5EDK 5EDK 5EDK 5EDK 5EDK
prothrombin deletion mutant residues 154-167 ( form i ) 2.20 Å 5EDM 5EDM 5EDM 5EDM 5EDM 5EDM
sandwiched between two dna aptamers: hd22 and hd1- deltat3 2.95 Å 5EW1 5EW1 5EW1 5EW1 5EW1 5EW1
sandwiched between two dna aptamers: hd22 and hd1- deltat12 3.59 Å 5EW2 5EW2 5EW2 5EW2 5EW2 5EW2
complex with hirunorm V 2.10 Å 5GDS 5GDS 5GDS 5GDS 5GDS 5GDS De et al., 1998
complex with avathrin 2.09 Å 5GIM 5GIM 5GIM 5GIM 5GIM 5GIM
Asp189Ala mutant 1.70 Å 5JDU 5JDU 5JDU 5JDU 5JDU 5JDU
complex with (s)-n-(2-(aminomethyl)-5-chlorobenzyl)-1- ((benzylsulfonyl)-d-arginyl)pyrrolidine-2-carboxamide 1.46 Å 5JFD 5JFD 5JFD 5JFD 5JFD 5JFD
complex with (s)-1-((r)-2-amino-3-cyclohexylpropanoyl)-n- (4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide 1.27 Å 5JZY 5JZY 5JZY 5JZY 5JZY 5JZY
complex with madanin 1.63 Å 5L6N 5L6N 5L6N 5L6N 5L6N 5L6N
complex with (s)-1-((r)-2-amino-3-cyclohexylpropanoyl)-n- (5-chloro-2-(hydroxymethyl)benzy l)pyrrolidine-2-carboxamide 1.39 Å 5LCE 5LCE 5LCE 5LCE 5LCE 5LCE
complex with (s)-1-((r)-2-amino-3-cyclohexylpropanoyl)-n- (2-(aminomethyl)-5-chlorobenzyl) pyrrolidine-2-carboxamide 1.50 Å 5LPD 5LPD 5LPD 5LPD 5LPD 5LPD
Ala190Ser mutant; complex with (s) -1 - ((r) -2-amino-3,3- diphenylpropanoyl) -n- (3-chlorobenzyl) pyrrolidine-2-carboxamide 1.40 Å 5MJT 5MJT 5MJT 5MJT 5MJT 5MJT
Ala190Ser mutant; complex with (s)-1-(d-phenylalanyl)-n-(3- chlorobenzyl)pyrrolidine-2-carboxamide 1.62 Å 5MLS 5MLS 5MLS 5MLS 5MLS 5MLS
Ala190Ser mutant; complex with (s)-1-(d-phenylalanyl)-n-(4- carbamimidoylbenzyl)pyrrolidine-2-carboxamide 1.29 Å 5MM6 5MM6 5MM6 5MM6 5MM6 5MM6
complex with anopheles gambiae ce5 anticoagulant 1.45 Å 5NHU 5NHU 5NHU 5NHU 5NHU 5NHU
Trp215Ala/Glu217Ala mutant fused to EGF456 of thrombomodulin via a 31-residue linker; complex with PPACK 2.34 Å 5TO3 5TO3 5TO3 5TO3 5TO3 5TO3
prothrombin mutant Ser101Cys/Ala470Cys 6.00 Å 6BJR 6BJR 6BJR 6BJR 6BJR 6BJR
crystal structure of human prothrombin mutant s101c/a470c 4.12 Å 6C2W 6C2W 6C2W 6C2W 6C2W 6C2W
reversible covalent direct thrombin inhibitors 2.90 Å 6CYM 6CYM 6CYM 6CYM 6CYM 6CYM
complex with a novel glucose-conjugated potent inhibitor 1.94 Å 6EO8 6EO8 6EO8 6EO8 6EO8 6EO8
complex with a novel glucose-conjugated potent inhibitor 1.84 Å 6EO9 6EO9 6EO9 6EO9 6EO9 6EO9
complex with nu172,a duplex/quadruplex 26-mer dna aptamer, in the presence of potassium ions. 2.50 Å 6EVV 6EVV 6EVV 6EVV 6EVV 6EVV
complex with 4-chloro-benzamidine 1.27 Å 6FJT 6FJT 6FJT 6FJT 6FJT 6FJT
complex with mi2100 ((s)-n-(2-(aminomethyl)-5- chlorobenzyl)-1-((benzylsulfonyl)-l-arginyl)pyrrolidine-2- carboxamide) 1.45 Å 6GBW 6GBW 6GBW 6GBW 6GBW 6GBW
complex with nu172,a duplex/quadruplex 26-mer DNA aptamer, in the presence of sodium ions. 2.80 Å 6GN7 6GN7 6GN7 6GN7 6GN7 6GN7
complex with SEL2711 inhibitor 2.10 Å 7KME 7KME 7KME 7KME 7KME 7KME Mochalkin & Tulinsky, 1999
complex with SEL2710 inhibitor 2.10 Å 8KME 8KME 8KME 8KME 8KME 8KME Mochalkin & Tulinsky, 1999
Mus musculus
mature  peptidase 2.20 Å 2OCV 2OCV 2OCV 2OCV 2OCV 2OCV Marino et al., 2007
mature  peptidase 2.00 Å 2PUX 2PUX 2PUX 2PUX 2PUX 2PUX Bah et al., 2007
mature  peptidase 3.50 Å 2PV9 2PV9 2PV9 2PV9 2PV9 2PV9 Bah et al., 2007
mature  peptidase 2.40 Å 3EDX 3EDX 3EDX 3EDX 3EDX 3EDX
mature  peptidase 1.94 Å 3HK3 3HK3 3HK3 3HK3 3HK3 3HK3 Gandhi et al., 2009
mature  peptidase 3.20 Å 3HK6 3HK6 3HK6 3HK6 3HK6 3HK6 Gandhi et al., 2009
mature  peptidase 2.20 Å 3HKI 3HKI 3HKI 3HKI 3HKI 3HKI Gandhi et al., 2009

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2023 EBI
Terms of use